Analysts think VTGN stock price could increase by 81%
Feb 09, 2026, 12:26 PM
7.64%
What does VTGN do
VistaGen Therapeutics, a biopharmaceutical company based in South San Francisco, develops treatments for anxiety and depression using intranasal pherines and other therapies targeting central nervous system disorders. The company’s pipeline includes five clinical-stage investigational agents and went public on October 18, 2010.
6 analysts think VTGN stock price will increase by 81.20%. The current median analyst target is $1.02 compared to a current stock price of $0.56. The lowest analysts target is $0.91 and the highest analyst target is $12.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.